ESSA Pharma Inc.'s (NASDAQ:EPIX) Hedge Funds Investors Lost 20% Last Week but Have Benefitted From Longer-term Gains
ESSA Pharma Inc.'s (NASDAQ:EPIX) Hedge Funds Investors Lost 20% Last Week but Have Benefitted From Longer-term Gains
Key Insights
主要见解
- Institutions' substantial holdings in ESSA Pharma implies that they have significant influence over the company's share price
- The top 4 shareholders own 55% of the company
- Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
- 机构在ESSA Pharma中的大量持股意味着他们对公司的股价具有重要影响。
- 前 4 大股东拥有公司的 55% 股份。
- 所有权研究和分析师预测数据有助于更好地了解股票市场的机会。
To get a sense of who is truly in control of ESSA Pharma Inc. (NASDAQ:EPIX), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 40% to be precise, is hedge funds. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
为了了解谁真正控制着ESSA Pharma Inc. (纳斯达克股票代码:EPIX),了解业务的所有权结构是很重要的。持有公司股份最多的一组,精确的说是约40%的对冲基金。换句话说,该组可能从其对公司的投资中获得最多的利润(或承受最多的损失)。
Losing money on investments is something no shareholder enjoys, least of all hedge funds investors who saw their holdings value drop by 20% last week. However, the 42% one-year return to shareholders may have helped lessen their pain. They should, however, be mindful of further losses in the future.
在投资中亏钱是任何股东都不享受的,特别是那些看到其持有股份价值上周下跌20%的对冲基金投资者。然而,为股东带来的一年42%的回报可能有助于减轻他们的痛苦。他们应该意识到今后可能会进一步亏损。
In the chart below, we zoom in on the different ownership groups of ESSA Pharma.
在下面的表格中,我们将聚焦于ESSA Pharma的不同所有权团体。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240614/0-431c9a8e90bbc3cd659f5443536d1b6c-0-8f13a03cbb741dc35f5c0eca9a6514c3.png/big)
What Does The Institutional Ownership Tell Us About ESSA Pharma?
机构所有权告诉我们关于ESSA Pharma的信息。
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
As you can see, institutional investors have a fair amount of stake in ESSA Pharma. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see ESSA Pharma's historic earnings and revenue below, but keep in mind there's always more to the story.
正如你所看到的,机构投资者在ESSA Pharma中持有相当大的股份。这意味着为这些机构工作的分析师已经看过这支股票,并且他们喜欢它。但就像其他人一样,他们也可能是错误的。当多个机构拥有一只股票时,总会有一个“拥挤的交易”风险。当这样的交易出现问题时,多个方可能会竞相快速出售股票。这种风险在一个没有增长历史的公司中更高。你可以在下面看到ESSA Pharma的历史收益和营业收入,但请记住,故事里总有更多内容。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240614/0-431c9a8e90bbc3cd659f5443536d1b6c-1-b69900add225909a11e2de69995a2c76.png/big)
Our data indicates that hedge funds own 40% of ESSA Pharma. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. BVF Partners L.P. is currently the company's largest shareholder with 20% of shares outstanding. With 18% and 9.4% of the shares outstanding respectively, Bellevue Asset Management AG and Morgan Stanley, Investment Banking and Brokerage Investments are the second and third largest shareholders.
我们的数据表明,对冲基金拥有ESSA Pharma的40%。这引起了我的注意,因为对冲基金有时会试图影响管理层或带来能够为股东创造短期价值的变化。BVF Partners L.P.目前是该公司的最大股东,持有20%以上的流通股。Bellevue Asset Management AG和Morgan Stanley,Investment Banking and Brokerage Investments分别持有18%和9.4%的流通股,是第二和第三大股东。
To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
为了使我们的研究更有趣,我们发现前四名股东控制了公司一半以上的股份,这意味着该集团对公司的决策具有相当大的影响力。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
尽管研究公司机构所有权数据是有意义的,但了解分析师的情绪也很有意义,以了解市场的走向。因为有很多分析师正在跟踪这个股票,所以看看他们的预测可能是值得的。
Insider Ownership Of ESSA Pharma
ESSA Pharma内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
内部人员的定义在不同国家可能会稍有不同,但董事会成员始终算入其中。公司管理负责经营业务,但即使首席执行官是董事会成员,他或她也必须对董事会负责。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
We can report that insiders do own shares in ESSA Pharma Inc.. In their own names, insiders own US$4.6m worth of stock in the US$205m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.
我们可以报告内部人员拥有ESSA Pharma股票。内部人员以自己的名义拥有2050万美元的股票。看到内部人员的一些投资是好事,但是查看这些内部人员是否一直在购买可能会更值得。
General Public Ownership
一般大众所有权
With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over ESSA Pharma. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
拥有19%的普通公众股东,主要包括个人投资者,对ESSA Pharma具有一定的影响力。尽管这种所有权规模很大,但如果决定与其他大股东不同步,则可能无法改变公司政策。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for ESSA Pharma you should be aware of, and 2 of them are concerning.
尽管考虑到拥有一家公司的不同团体是值得的,但还有其他更重要的因素。例如:我们发现ESSA Pharma有3个警告信号,其中2个令人担忧。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果您想发现分析师对未来增长的预测,请不要错过这份有关分析师预测的免费报告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。